Ingrid Isakov Kyriakakis, MD
Geriatric Medicine · Anderson, SCNPI 1417081282
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $510 and has fallen 54.9% since, to $230 in 2025.
Across 144 payments — averaging $14.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$275
- Bayer$259
- Novartis$220
- AstraZeneca$187
- Boehringer Ingelheim$173
- GSK$135
- plus $799 from 18 others
What the payments were for
- Food & beverage$2,048100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 15 | $275 |
| Bayer | 28 | $259 |
| Novartis | 16 | $220 |
| AstraZeneca | 15 | $187 |
| Boehringer Ingelheim | 13 | $173 |
| GSK | 8 | $135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $128 |
| Boston Scientific | 4 | $85 |
| Novo Nordisk | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 5 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Merck | 4 | $49 |
| Medtronic | 2 | $46 |
| Lilly USA, LLC | 3 | $44 |
| Amgen | 3 | $42 |
| Insulet Corporation | 2 | $42 |
| Pfizer | 3 | $40 |
| Johnson & Johnson | 2 | $25 |
| AbbVie | 1 | $24 |
| Edwards Lifesciences | 1 | $22 |
| Dexcom, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $12 |
How this compares
$2,048 in reported general payments places this provider in the 85th percentile of 41 geriatric medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 99 | $98,101 |
| OzempicSemaglutide | 89 | $94,312 |
| EliquisApixaban | 105 | $92,091 |
| JardianceEmpagliflozin | 73 | $74,216 |
| TrulicityDulaglutide | 17 | $43,753 |
| MyrbetriqMirabegron | 51 | $41,418 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $23,791 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $21,451 |
| MounjaroTirzepatide | 16 | $16,940 |
| Repatha SureclickEvolocumab | 14 | $15,947 |
| XareltoRivaroxaban | 16 | $14,078 |
| TradjentaLinagliptin | 14 | $11,562 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $10,387 |
| Atorvastatin Calcium | 1,058 | $7,610 |
| Praluent PenAlirocumab | 15 | $7,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $49 | $98,10199 claims |
| Novo NordiskOzempic | $83 | $94,31289 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $173 | $92,23798 claims |
| PfizerEliquis | $40 | $92,091105 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $44 | $60,69333 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $41,41851 claims |
| Johnson & JohnsonXarelto | $25 | $14,07816 claims |
| BayerKerendia | $259 | $6,96611 claims |
| AbbVieSynthroid | $24 | $6,46784 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 41 geriatric medicine providers in South Carolina.
Other geriatric medicine in Anderson
- Vipin VermaAnderson$386
- Rajiv JoglekarAnderson$137
- John KleckleyColumbia$19K
- Fariha SultanGreenville$6K
- Joseph GarandPiedmont$4K
- William ChildersLaurens$4K
- Lester SalwenGreenville$3K
- Marion DavisSumter$2K
- Macdonald DuboseSumter$988
- Barto KellettGreenville$664
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.